drugset / Trial / NCT04931368
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
Phase 3
Active not recruiting
331 enrolled
Klinikum Stuttgart
German Federal Ministry of Education and Research · collabUniversity Hospital Freiburg · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase III study investigates if a de-escalated induction treatment in newly diagnosed primary CNS lymphoma is superior to the standard MATRix protocol in terms of event free survival.
Timeline
- Start
- 2021-06-28
- Primary completion
- 2028-06
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 2 g | Intravenous |
| Subject | Methotrexate | Small molecule | 3.5 g | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Thiotepa | Other / unclassified | 5 mg/kg | Intravenous |
| Subject | Thiotepa | Other / unclassified | 30 mg/m2 | Intravenous |